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Abstract
Background: Tumor necrosis factor-a (TNF-a), a proinflammatory cytokine, is capable of activating the small
GTPase RhoA, which in turn contributes to endothelial barrier dysfunction. However, the underlying signaling
mechanisms remained undefined. Therefore, we aimed to determine the role of protein kinase C (PKC) isozymes in
the mechanism of RhoA activation and in signaling TNF-a-induced mouse brain microvascular endothelial cell
(BMEC) barrier dysfunction.
Methods: Bend.3 cells, an immortalized mouse brain endothelial cell line, were exposed to TNF-a (10 ng/mL).
RhoA activity was assessed by pull down assay. PKC-a activity was measured using enzyme assasy. BMEC barrier
function was measured by transendothelial electrical resistance (TER). p115RhoGEF phosphorylation was detected
by autoradiography followed by western blotting. F-actin organization was observed by rhodamine-phalloidin
staining. Both pharmacological inhibitors and knockdown approaches were employed to investigate the role of
PKC and p115RhoGEF in TNF-a-induced RhoA activation and BMEC permeability.
Results: We observed that TNF-a induces a rapid phosphorylation of p115RhoGEF, activation of PKC and RhoA in
BMECs. Inhibition of conventional PKC by Gö6976 mitigated the TNF-a-induced p115RhoGEF phosphorylation and
RhoA activation. Subsequently, we found that these events are regulated by PKC-a rather than PKC-b by using
shRNA. In addition, P115-shRNA and n19RhoA (dominant negative mutant of RhoA) transfections had no effect on
mediating TNF-a-induced PKC-a activation. These data suggest that PKC-a but not PKC-b acts as an upstream
regulator of p115RhoGEF phosphorylation and RhoA activation in response to TNF-a. Moreover, depletion of PKC-
a, of p115RhoGEF, and inhibition of RhoA activation also prevented TNF-a-induced stress fiber formation and a
decrease in TER.
Conclusions: Taken together, our results show that PKC-a phosphorylation of p115RhoGEF mediates TNF-a
signaling to RhoA, and that this plays a critical role in signaling F-actin rearrangement and barrier dysfunction in
BMECs.
Background
The integrity of brain microvascular endothelial cells
(BMECs) is the basis of the maintenance of the central
nervous system (CNS) microenvironment [1]. Tumor
necrosis factor-a (TNF-a) is released in large amounts
by macrophages, monocytes and other leukocytes in
response to gram-positive or gram-negative bacterial
substances, and plays a vital role in the pathogenesis of
infectious brain edema [2]. RhoA has been implicated in
signaling by TNF-a, lysophosphatidic acid (LPA), and
hepatocyte growth factor (HGF), and is known to play a
critical role in regulating endothelial barrier function
[3]. We previously demonstrated that elevated TNF-a is
highly correlated with the occurrence of blood brain
barrier (BBB) dysfunction, and that inhibiting Rho
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edema in animals after TNF-a challenge [4]. Thus, these
findings suggest an essential role for the RhoA/Rho
kinase pathway in the regulation of TNF-a-induced
BMECs barrier dysfunction. However, little is known
about the complex signaling events regulating RhoA, by
which TNF-a plays a role in BMEC barrier dysfunction.
RhoA serves as a molecular switch, cycling between
active GTP-bound and inactive GDP-bound states regu-
lated by a large number of activators and inactivators,
including guanine nucleotide exchange factors (GEFs),
GTPase-activating proteins (GAPs), and guanine nucleo-
tide dissociation inhibitors (GDIs). Activation of RhoA
requires GDP/GTP exchange, which is controlled by
GEFs. More than 80 RhoGEFs have been identified, with
the characteristic of containing a Dbl homology (DH)
domain as well as a pleckstrin homology (PH) domain
[5]. Among several GEFs identified, p115RhoGEF can
directly link heterotrimeric Ga12/13 subunits to RhoA
regulation [6,7]. It has been shown that thrombin binds
to and cleaves protease-activated receptor (PAR-1) in
endothelial cells, leading to activation of heterotrimeric
G-protein Gq1, Gi, and Ga12/13 [8]. Several studies
have shown that the p115RhoGEF/RhoA pathway is
required for several stimuli such as thromboxane A2
and LPA-induced endothelial barrier leakage [9,10].
Thus, these studies suggest that TNF-a induces BMEC
hyperpermeability, possibly through a p115RhoGEF/
RhoA-dependent mechanism.
Protein kinase C isozymes are serine-hreonine kinases
that phosphorylate multiple proteins, which in turn reg-
ulate intracellular signaling. We previously showed in
vitro that LPA-induced BBB breakdown was associated
with activation of PKC and was prevented by the PKC
inhibitor Ro31-8220 by down-regulating the claudin-5
expression and F-actin recombination [11]. Several stu-
dies have demonstrated a convergence between PKC
and the RhoA pathway in regulating endothelial barrier
dysfunction [12]. PKC-a and RhoA coimmunoprecipi-
tate in the particulate fraction of colon smooth muscle
cells in response to different contactile agonists [13].
A recent study suggests that PKC-a can trigger RhoA
activation and promote actin cytoskeletal changes in
thrombin-induced endothelial cell hyperpermeability
[ 1 4 ] .I ti sa s s u m e dt h a tP K Cs i g n a l i n gi si n v o l v e di n
RhoA activation and subsequently endothelial barrier
breakdown. Taken together, these data suggested the
possibility that PKC and p115RhoGEF work together in
RhoA activation and endothelial barrier dysfunction.
However, there are no studies on how PKC and
p115RhoGEF signaling interact in the pathogenesis of
TNF-a-induced RhoA activation and barrier dysfunction
in BMECs.
Here we took advantage of both pharmacological inhi-
bitors and knockdown approaches to investigate the role
of PKC and p115RhoGEF in TNF-a-induced RhoA acti-
vation and BMEC permeability. Our data show that
PKC-a but not PKC-b mediates p115RhoGEF phosphor-
ylation, which in turn triggers RhoA activation, and then
promotes F-actin rearrangement and barrier permeabil-
ity in BMECs in response to TNF-a.
Methods
Reagents
Anti-p115RhoGEF, PKC-a and PKC-b were purchased
from Santa Cruz Biotechnology (San Diego, CA, USA).
HRP-linked anti-goat and -rabbit IgG, and RhoA antibo-
dies, were purchased from Cell Signaling (Beverly, MA,
USA). A RhoA pull-down kit containing GST-RhoAte-
kin-RhoA-binding domain beads was purchased from
Cytoskeleton (Denver, CO, USA). TNF-a was obtained
from Sigma Chemical (St. Louis, MO, USA). Gö6976
was purchased from Calbiochem (Gibbstown, NJ, USA).
Fibronectin-coated cell inserts with 0.4 μmp o r es i z e
were obtained from BD Biosciences (Franklin Lakes, NJ,
USA). Lipofectamine 2000 and rhodamine-phalloidin
were purchased from Invitrogen (Carlsbad, CA, USA).
Cell culture
Bend.3 cells, mouse brain-deprived microvascular
endothelial cells, were kindly afforded by Dr. Zhang Jian
(The University of Chicago, Chicago, USA) and were
cultured in Dulbecco’s modified Eagle’sm e d i u m
(DMEM) containing 10% (v/v) fetal bovine serum at
37℃ 5% CO2. Culture medium was changed every 2
days. All experiments were performed in confluent
monolayers on day 9 or 10 post seeding.
Plasmids and transfection
PcDNA3.1hygro-n19RhoA plasmid, the dominant nega-
tive mutant of RhoA, was synthesized in Minghong CO
(CHN). This mutant was obtained by in vitro site-direc-
ted mutagenesis of Thr to Asn at codon 19, which
maintains RhoA in an inactive GDP-loaded state. An
expression vector containing PcDNA3.1hygro plasmid
alone served as the control of the PcDNA3.1hygro-
n19RhoA plasmid.
PLKO.1-puro-PKCa-shRNA and PLKO.1-puro-PKCb-
shRNA were gifts from Dr. Zhang Jian (The University
of Chicago, Chicago, USA). P115RhoGEF-shRNA was
purchased from Shanghai GeneChem Co (CHN), and
was constructed into the PLKO.1-puro expression vec-
tor. An empty PLKO.1-puro vector was used as the con-
trol for the PKCa-shRNA and p115RhoGEF-shRNA
plasmids.
All of the plasmids were introduced into Bend.3 cells by
using Lipofectamine 2000 according to the manufacturer’s
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(n19RhoA) and Bend.3/PcDNA3.1hygro cells (vector-1)
were obtained by using the Hygromycin B (400 ug/ml,
Sigma) selection method after transfection. The Bend.3
cells transfected with PLKO.1-puro-PKCa-shRNA,
PLKO.1-puro-PKCb-shRNA, PLKO.1-puro-p115RhoGEF-
shRNA and empty PLKO.1-puro plasmids were called
PKCa-shRNA, PKCb-shRNA, p115-shRNA and vector-2
cells respectively. All of them were used for experiments
after selection by Puromycin (300 ug/ml). The inhibition
levels of RhoA activity and PKC-a expression as well as
p115RhoGEF were detected by pull-down assay and wes-
tern blot respectively.
Assay of activated RhoA
RhoA activity was measured using a RhoA pull-down kit
according to the manufacturer’s protocols. Briefly, sub-
confluent cell cultures were starved with serum-free
medium for 6 hours, then stimulated by TNF-a before
an ice-cold PBS rinse and lysis in 500 μl of the supplied
lysis buffer. Equal volumes of supernatants were incu-
bated with RhoAtekin-RBD affinity beads for 1 hour at
4°C, followed by two washes in lysis buffer and three
washes in the supplied wash buffer. Bound proteins
were eluted in 5 × 1% SDS sample buffer and examined
by 12% SDS-PAGE and western blot with anti-RhoA
antibody analysis. Aliquots of total lysate were also ana-
lyzed for the amount of RhoA present.
PKC-a kinase activity assay
PKC-a activity was measured using PKC-a Assay Kits.
Cell cultures were starved with serum free medium for 6
hours then stimulated by TNF-a before an ice-cold PBS
rinse and lysis in 500 μl of NP-40 lysis buffer. The cell
lysates were then incubated in PKC-a antibody (2 ug
antibody/800 ug protein) with a rotor shaker, at 4°C over-
night. Then 20 ul ProteinA/G agarose were added into
the cell lysates, which were then centrifuged and washed
with PBS 5 times. After a final aspiration, 5 uL of
KRREILSRRPSYR substrate, 5 uL of the ATP solution,
and 15 ul PKC kinase buffer were added to initiate the
kinase reaction which was carried out at 30-35°C for 60
min with constant shaking. The kinase reaction was
stopped with 20 uL 2 × SDS-sample loading buffer and
boiling for 2 min. Results were then examined using 12%
SDS-PAGE and western blot with anti-KRREILSRRP-
pSYR antibody analysis.
Measurement of transendothelial electrical resistance
(TER)
Endothelial permeability was assayed by measuring TER
using a Millicell ERS Voltohmmeter (Millipore, Billerica,
MA, USA), and the values are shown as Ω￿cm2 based on
culture inserts. The TER of cell-free inserts was subtracted
from the TER of filters with cells. The TER of cells was
measured before and after treatment with TNF-a.
Actin staining
Cell monolayers were stained with Rhodamine-phalloidin
to examine the structure of filamentous (F)-actin. Washed
cells were fixed with polyoxymethylene, washed again, and
permeabilized for 5 min with 0.1% Triton X-100. The cells
were incubated with a 1% solution of BSA (30 min, RT),
and stained with Rhodamine-phalloidin (0.20 mol/L,
30 min, RT, in dark conditions). Stained F-actin was visua-
lized using an OLYMPUS XB-51 fluorescence inverted
microscope under 200-fold magnification.
Immunoblot analysis
Protein samples (30 μg total protein per lane) were sub-
jected to 8% or 12% SDS-PAGE, and the proteins were
then electrophoretically transferred to a polyvinylidene
fluoride (PVDF) membrane blocked by 5% BSA for 1 h
at room temperature and then incubated with antibodies
overnight at 4°C. Secondary antibody was incubated for
1 h at room temperature. A chemiluminescence reagent,
ECL western blotting detection reagent (Amersham
Biosciences Corp., Arlington Heights, IL, USA), was
used to make the labeled protein bands visible. The
blots were developed by the enhanced chemilumines-
cence method (Amersham).
Phosphorylation of p115RhoGEF
After serum deprivation for 6 h, BMECs were labeled with
150 uCi/ml
32P for 4 h in phosphate-free MEM. Cells
were then stimulated with TNF-a (10 ng/ml) for the indi-
cated times, quickly transferred onto ice, washed with ice-
cold PBS containing 500 uM Na3VO4 and lysed. After
centrifugation, the cleared lysate was incubated with either
control IgG or anti-mouse P115RhoGEF Ab for 2 h fol-
lowed by the addition of protein A/G plus agarose beads
overnight. The beads were then collected by centrifuga-
tion, washed with detergent-free buffer and 2 ug/mL each
of pepstatin A, leupeptin, and aprotinin. The above proce-
dures were performed at 4°C. Protein from each sample
was eluted by boiling the beads in SDS sample buffer, elec-
trophoresing on 8% SDS-polyacrylamide gels, and transfer
to nitrocellulose for visualization of p115RhoGEF phos-
phorylation by autoradiography, followed by western blot-
ting with p115RhoGEF antibody to verify equal protein
loading. Specificity of the p115RhoGEF antibody was con-
firmed using normal mouse IgG as a negative control.
Statistical analyses
All of the data are expressed as the means ± SD. A Stu-
dent’s t-test was performed to determine the significant
difference between two groups. One-way ANOVA ana-
lysis followed by Student-Neuman-Keuls post-hoc tests
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among multiple groups. P < 0.05 was considered to be
statistically significant.
Results
TNF-a activates RhoA, mediating barrier dysfunction in
Bend.3 cells
To address the direct involvement of RhoA in TNF-a-
induced Bend.3 cell barrier permeability, n19RhoA cells
(dominant negative mutant of RhoA) were used to sup-
press activation of RhoA. The remarkable inhibitory
effect of n19RhoA was confirmed by pull-down assay
(Figure 1A).
TNF-a (10 ng/ml) exposure induced rapid and pro-
longed RhoA activation in a time-course manner. RhoA
activity increased significantly at 1 min, with a maxi-
mum response occurring at 30 min followed by a
decline at 3 h. However, RhoA activity remained higher
than the baseline even 12 h after TNF-a administration
(Figure 1B).
Measurements of transendothelial electrical resistance
(TER) reflecting endothelial monolayer permeability
changes showed that administration of TNF-a (10 ng/
ml) resulted in a time-dependent decrease in TER. The
TER of vector-1 cells and n19RhoA cells without TNF-
a challenge remained stable enough to be regarded as
Figure 1 TNF-a activates RhoA, which mediates barrier dysfunction in Bend.3 cells. (A) PcDNA3.1hygro-n19RhoA (the dominant negative
mutant of RhoA), and PcDNA3.1hygro vector plasmids (vector-1) were transfected into Bend.3 cells by Lipofectamine 2000. Stably transfected
cells were obtained using the Hygromycin B (400 ug/ml) selection method after transfection. Untreated Bend.3 cells served as controls. The
inhibitory effect of n19RhoA was confirmed by pull-down assay. (B) Levels of active RhoA in vector-1 cells after TNF-a (10 ng/ml) treatment
were detected at various time points by pull-down assay to detect relative amounts of RhoA-GTP. Total RhoA levels served as loading controls.
The results show that TNF-a induced a rapid activation of RhoA within 1 min, reaching peak activation within 30 min. (n = 3 independent
experiments). (C) Vector-1- and n19RhoA-transfected cells were treated with or without TNF-a for various time periods. TER assay was used to
determine Bend.3 monolayer permeability. The results show that TNF-a-induced vector-1 cell barrier breakdown was partially alleviated in
n19RhoA cells. *: p < 0.05 vs. Vector-1, #: p < 0.05 vs. Control, △: p < 0.05 vs. Vector-1+TNF-a n = 4/group.
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vector-1 cells with TNF-a dropped to the lowest level at
12 h. However, inhibiting RhoA activity with n19RhoA
cells significantly suppressed decreases in TER in
response to TNF-a (Figure 1C). These data indicate that
TNF-a activate RhoA, which mediates barrier dysfunc-
tion in Bend.3 cells.
TNF-a-induced RhoA activation is secondary to PKCa
activation
To address the question of whether PKC acts upstream
of RhoA activation, Gö6976, a selective inhibitor of con-
ventional PKC isoenzymes, was used to inhibit the activ-
ity of PKC-a and PKC-b. Gö6976 pretreatment of
Bend.3 cells blocked TNF-a-induced RhoA activation,
implicating conventional PKC as an upstream regulator
of RhoA activation (Figure 2A).
To identify the specific conventional PKC isozymes
regulating the activation of RhoA, PKCa-ShRNA and
PKCb-ShRNA were used. The significant knockdown
effect of PKCa-ShRNA (Figure 2B, middle) and PKCb-
shRNA (Figure 2B, bottom) was confirmed by western
blot. As shown in Figure 2A, depletion of PKC-b failed
to abrogate RhoA activation in response to TNF-a in
Bend.3 cells, while knockdown PKC-a significantly
blocked RhoA activation. These data provide unequivo-
cal evidence that PKC-a but not PKC-b is critical in sti-
mulating TNF-a-induced RhoA activation.
To further confirm if PKC-a is the upstream regulator
of RhoA, the time course of PKC-a and RhoA activation
was compared, and the effects of n19RhoA transfection
on PKCa activation were assessed. Although TNF-a
induced rapid activation of PKC-a as well as RhoA at
the same time (Figure 2C), n19RhoA expression had no
effect on mediating changes of PKC-a activity in Bend.3
cells (Figure Four B). This finding indicates that PKC-a
signaling acts as an upstream regulator in TNF-a-
induced RhoA activation in Bend.3 cells.
TNF-a-induced RhoA activation is secondary to
p115RhoGEF phosphorylation
To address the question of whether p115RhoGEF phos-
phorylation is also involved in TNF-a-induced RhoA acti-
vation, P115-shRNA was used to deplete p115RhoGEF
expression. The remarkable knockdown effect of P115-
shRNA was confirmed by western blot (Figure 2B, upper).
Figure 3A shows the autoradiograph of p115RhoGEF
phosphorylation in
32P. The results show that TNF-a
induced a surprisingly fast p115RhoGEF phosphoryla-
tion reaching maximum at 1 min (Figure 3). P115-
shRNA transfected cells prevented TNF-a-induced
RhoA activation, implicating p115RhoGEF as one of the
upstream regulators of RhoA activation in response to
TNF-a (Figure 2A).
PKC-a but not PKC-b activation is the upstream signal in
TNF-a-induced p115RhoGEF phosphorylation
An attempt was made to explore if PKC-a is the
upstream signal for TNF-a-mediated p115RhoGEF
phosphorylation in BMECs. We found that depletion of
PKC-a by Gö6976 or PKCa-ShRNA prevented the
phosphorylation of p115RhoGEF in response to TNF-a,
whereas depletion of PKC-b by PKCb-ShRNA had no
effect on p115RhoGEF phosphorylation (Figure 4A).
Our experiment further demonstrated that P115-shRNA
transfection attenuates p115RhoGEF expression, but has
no effect on PKC-a activation (Figure 4B). These data
suggest that PKC-a but not PKC-b acts as an upstream
regulator of p115RhoGEF phosphorylation in TNF-a
challenge.
Role of the PKC-a/p115RhoGEF/RhoA pathway in TNF-a-
induced F-actin rearrangement and BMEC barrier
dysfunction
We analyzed the effect of RhoA inactivation, P115Rho-
GEF and PKC-a knockdown on TNF-a-induced F-actin
dynamics by immunofluorescence (Figure 5A) and bar-
rier permeability by TER (Figure 5B). Before stimulation,
Bend.3 cells did not display stress fibers although they
exhibited an extensive cortical actin network (Figure 5A.
a,e). After 3 h of TNF-a exposure, cells exhibited pro-
minent stress fiber formation and paracellular gaps
(Figure 5A.b,f). However, the stress fiber formation and
intra-cellular gaps induced by TNF-a were reduced by
inhibiting the activation of RhoA (Figure 5A.c-d),
p115RhoGEF (Figure 5A. g-h) and PKC-a (Figure 5A.
i-j). Furthermore, as shown from Figure 5 B, after expo-
sure to TNF-a for 12 h, the TER of cells with p115Rho-
GEF depletion and PKC-a displayed as 67.8 ± 2.49 and
60.5 ± 3.64 Ω￿cm
2, higher than that of vector-2 cells
(47 ± 1.87 Ω￿cm
2). This indicates inhibition of RhoA
activation (Figure 1D), and suggests that depletion of
p115RhoGEF and PKC-a could alleviate TNF-a-induced
barrier breakdown. Moreover, according to our data, the
inhibitor of p115RhoGEF acted more efficiently than the
inhibitor of PKC-a in repairing the TER.
Discussion
BMECs, which are linked by tight junctions, act as a
physical and metabolic barrier to shield the brain from
toxic substances in the blood, supply brain tissues with
nutrients, and filter harmful compounds from the brain
back into the bloodstream [15]. However, the normal
physiological functions of the endothelium are perturbed
during serious sepsis. It has been shown that TNF-a
contributes to endothelial barrier breakdown and
cytokine transport across the blood-brain barrier (BBB)
in sepsis [16]. Direct i.v. injection of recombinant
TNF-a also can induce BBB opening [17]. Therefore,
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TNF-a in BMECs is paramount to understanding the
mechanisms of infectious brain edema.
RhoA is a key regulator of cytoskeletal dynamics, actin
stress fiber formation, and myosin phosphorylation, and
thus by inference, in the control of endothelial barrier
function [18,19]. However, the involvement of RhoA sig-
naling has recently been challenged. Opposing studies
have indicated that Y-27632 does not counteract either
histamine-induced microvascular leakage in the airway
[20] or an LPS-induced increase in permeability of skele-
tal muscle [21]. It is possible that different cell types and
different stimuli regulate different signal transduction
pathways for altering endothelial cell permeability. In our
study, TNF-a (10 ng/mL) induces a robust activation of
RhoA from 1 min up to 12 h (Figure 1B). The TER of
Bend.3 and vector-1 with TNF-a decreased at 30 min,
and dropped to the lowest level at 12 h. However, down-
regulation of RhoA activation by n19RhoA, a dominant
negative mutant of RhoA, remarkably suppressed TER
decrease in response to TNF-a treatment (Figure 1C).
These data suggest that RhoA participates in TNF-a-
induced mouse BMEC barrier dysfunction. However, the
mechanisms of the activation of RhoA, and thereby the
loss of endothelial barrier integrity, have not been
elucidated.
Figure 2 Protein kinase C-a and p115RhoGEF regulate TNF-a-induced RhoA activation. (A) Bend.3 cells were pretreated with or without
Gö6976 (1 μM), a selective inhibitor of conventional PKC isozymes. RhoA activation was assayed after 5 min of TNF-a challenge. The results
show that Gö6976 pretreatment of Bend.3 cells blocked TNF-a-induced RhoA activation. Bend.3 cells were transfected with vector-2(empty
PLKO.1-puro vector), PKCa-shRNA, PKCb-shRNA or p115-shRNA in the presence or absence of TNF-a. RhoA activation was partially prevented in
PKCa-shRNA and P115-shRNA transfected cells, whereas RhoA activation did not affect PKCb-shRNA transfected cells. (B) The Bend.3 cells
transfected with vector-2, PKCa-shRNA, PKCb-shRNA and p115-shRNA respectively. Stably transfected cells were used for experiments after
selection by Puromycin (300 ug/ml). The inhibitory levels of p115RhoGEF (upper), PKC-a (middle) and PKC-b (bottom) expression were confirmed
by western blot. (C) The time course of PKC-a and RhoA activation after TNF-a (10 ng/ml) treatment was detected. The results showed that
TNF-a-induces rapid activation of PKC-a as well as RhoA at 0.5 min. (n = 3 for each condition). *: p < 0.05 vs. Vector-2, △: p < 0.05 vs. untreated
Bend.3 cells. -, absence; +, presence.
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factors, provides a direct pathway for regulation of RhoA,
in this study we addressed the basis of RhoA activation
and its contribution in mediating the loss of endothelial
barrier function induced by TNF-a. RhoGEF catalyses the
exchange of GDP for GTP by promoting an active confor-
mation of the small monomeric GTPase RhoA, which
enables the recruitment of effector proteins that mediate
Figure 3 TNF-a induces P115RhoGEF phosphorylation in Bend.3 cells. Serum-starved cells were labeled with
32P for 4 h in phosphate-free
medium. Bend.3 cells were then stimulated with TNF-a for the indicated times and p115RhoGEF phosphorylation was detected by
autoradiography followed by western blotting. Untreated Bend.3 cells served as controls. TNF-a induced rapid p115RhoGEF phosphorylation
within 1 min. (n = 3 independent experiments). *P < 0.05 vs. Control. -, absence; +, presence.
Figure 4 PKC-a but not PKC-b is the upstream signal in TNF-a-induced P115RhoGEF phosphorylation. (A) Serum-starved cells were
transfected with vector-2, PKCa-shRNA, PKCb-shRNA or pretreated with Gö6976. Serum-starved cells were then labeled with
32P for 4 h in
phosphate-free medium. Cells were stimulated with TNF-a for 1 min, and then p115RhoGEF phosphorylation was detected by autoradiography
followed by western blotting. The results show that depletion of PKC-a by Gö6976 or PKCa-ShRNA prevents the phosphorylation of
p115RhoGEF in response to TNF-a. In contrast, depletion of PKC-b isozyme expression by using PKCb-shRNA had no effect on P115RhoGEF
phosphorylation. (B) Serum-starved cells were transfected with vector-1, n19RhoA, vector-2 and P115-shRNA. Cells were stimulated with TNF-a
for 1 min, and then PKC-a activation was detected by vitro enzyme assasy. The results show that n19RhoA and P115-shRNA transfections had no
effect on PKC-a activation. (n = 3 for each condition). *: p < 0.05 vs. Vector-2, △: p < 0.05 vs. Vector-1.-, absence; +, presence.
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Ga12/13 and RhoA, recruitment of p115RhoGEF to the
plasma membrane has been observed in response to LPA
and thromboxane A2 [25,26]. It has been reported that
activation of the serum response factor (SRF) is not only
dependent on Ga12/13-linked GPCRs and RhoA, but also
on over-expression of p115RhoGEF [27]. It is possible that
TNF-a activates RhoA, resulting in up-regulation of
p115RhoGEF. Our data also show that TNF-a induces
rapid phosphorylation of p115RhoGEF in Bend.3 cells that
could be detected at 1 min (Figure 3). Depletion of
p115RhoGEF in Bend.3 cells greatly impaired RhoA acti-
vation (Figure 2A) and attenuated BMEC barrier dysfunc-
tion (Figure 1C) in response to TNF-a, indicating a
critical role for P115RhoGEF in TNF-a-associated RhoA
activation.
Aside from Ga12/13 directly stimulating the exchange
activity of p115RhoGEF on RhoA, there may be additional
regulatory pathways contributing to p115RhoGEF
phosphorylation. Our previous study showed that PKC-a
is expressed in primary cultured BMECs and astrocytes.
Inhibition of PKC attenuates LPA-induced BBB perme-
ability [11]. How PKC alters endothelial permeability
remains an interesting question. Several studies have sug-
gested that the endothelial contractile response could be
triggered by a PKC-dependent activation of the RhoA
pathway [28-30]. TNF-a induces a time-dependent
increase in PKC mRNA expression and RhoA activation
in vascular tissues [31]. More specifically, conventional
PKC phosphorylates Rho-GDP dissociation inhibitor
(GDI) on serine 34, resulting in a specific decrease in affi-
nity for RhoA, leading to nucleotide exchange and interac-
tion with downstream effectors [32]. Furthermore, PKC is
a phospholipid-dependent serine/threonine kinase
involved in diverse intracellular signal transduction
processes [33]. Since p115RhoGEF contains a sequence for
Figure 5 Role of the PKC-a/P115RhoGEF/RhoA pathway in TNF-a-induced F-actin rearrangement and BMEC barrier dysfunction. (A) F-
actin remodeling and paracellular gap formation were detected by immunofluorescence. Serum-starved cells were transfected with vector-1,
n19RhoA, vector-2, P115-shRNA and PKCa-shRNA for 3 h with either DMEM (left) or TNF-a (right). Before stimulation, Bend.3 cells did not display
stress fibers although they exhibited an extensive cortical actin network (Figure 5A.a,e). After 3 h of TNF-a exposure, cells exhibited prominent
stress fiber formation and paracellular gaps (Figure 5A.b,f), which were partially prevented by inhibition of RhoA activation (Figure 5c-d), and
depletion of p115RhoGEF (Figure 5g-h) as well as PKC-a expression (Figure 5 i-j). (n = 3 independent experiments). (B) Vector-2, P115-shRNA and
PKCa-shRNA transfected cells were treated with or without TNF-a for various time periods. Bend.3 monolayer permeability was determined by
TER. The results show that knockdown of p115RhoGEF and PKC-a can alleviate TNF-a-induced barrier breakdown. *: p < 0.05 vs. vector-2, △:p<
0.05 vs. vector-2 +TNF-a, n = 4/group.
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Page 8 of 10phosphorylation, we addressed the possibility that PKC
may mediate RhoA activation by inducing the phosphory-
lation of p115RhoGEF.
Our results provide several lines of evidence that
p115RhoGEF phosphorylation and RhoA activation are
mediated by a PKC-dependent pathway in BMECs. We
show that TNF-a-induced p115RhoGEF phosphoryla-
tion occurs concurrently with TNF-a-induced activation
of RhoA. Furthermore, inhibition of PKC by Gö6976, a
specific conventional isozyme-selective inhibitor of PKC,
abrogated not only TNF-a-induced RhoA activation but
also p115RhoGEF phosphorylation. Subsequently, we
narrowed this effect specifically to PKC-a by using both
pharmacological inhibitors and knockdown approaches.
Our results reveal that treatment of BMECs with PKCb-
shRNA fails to prevent RhoA activation and p115Rho-
GEF phosphorylation in response to TNF-a.H o w e v e r ,
knockdown of PKC-a by PKCa-ShRNA successfully
blocked marked RhoA activation and p115RhoGEF
phosphorylation. In addition, P115-shRNA and
n19RhoA transfection had no effect on mediating TNF-
a-induced PKC-a activation. Taken together, these
results indicate that PKC-a is critical in regulating TNF-
a-induced p115RhoGEF phosphorylation and RhoA
activation in BMECs.
BMEC permeability is precisely controlled by cell
contact protein complexes (focal adhesions, adherens
junctions and tight junctions) and cytoskeletal elements
(F-actin, microtubules, and intermediate filaments)
[34,35]. F-actin plays an important role in maintaining
the integrity of the tight junction complex, and therefore
in modulating the permeability of the BBB [36,37].
Reduction of TER and rearrangement of F-actin are
good indicators of barrier dysfunction. Here we detected
them to observe the functional relevance of PKC-a/
p115RhoGEF/RhoA pathway in signaling endothelial
barrier disruption. The results show that TNF-a causes
a significant decrease in TER in BMECs transfected with
vector-2 alone (Figure 5B). However, this response was
significantly reduced in cells transfected with n19RhoA
(Figure 1D), p115-shRNA or PKCa-shRNA (Figure 5B).
These effects were accompanied by decreases in
the amount of stress fibers and paracellular gaps
(Figure 5A). Thus, these results indicate that the PKC-
a/p115RhoGEF/RhoA pathway is the mechanism med-
iating TNF-a-induced dynamics of F-actin and elevation
of BMEC permeability, which in turn might contribute
to infectious brain edema.
Conclusion
Collectively, our data provide the first direct evidence
that PKC-a phosphorylation of p115RhoGEF is involved
in TNF-a-induced RhoA activation, and that this plays a
critical role in signaling increased barrier permeability in
mouse brain endothelial cells.
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